<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Thromboses of the deep veins (DVT) and potential complications are disorders with which physicians need to be well familiarized so they can be recognized and managed </plain></SENT>
<SENT sid="1" pm="."><plain><z:e sem="disease" ids="C0398623" disease_type="Disease or Syndrome" abbrv="">Hypercoagulable states</z:e> play a significant role in the development of DVT and these disorders must be suspect when <z:mp ids='MP_0005048'>thrombosis</z:mp> occurs, especially in the upper extremities </plain></SENT>
<SENT sid="2" pm="."><plain><z:hpo ids='HP_0003613'>Antiphospholipid antibody</z:hpo> syndrome (APS) is one such <z:e sem="disease" ids="C0398623" disease_type="Disease or Syndrome" abbrv="">hypercoagulable state</z:e> in which autoantibodies are formed against anionic <z:chebi fb="0" ids="16247">phospholipid</z:chebi> complexes </plain></SENT>
<SENT sid="3" pm="."><plain>In vivo, these antibodies cause a <z:e sem="disease" ids="C0398623" disease_type="Disease or Syndrome" abbrv="">hypercoagulable state</z:e> through a number of proposed mechanisms, whereas in vitro they interfere with the assembly of <z:chebi fb="0" ids="16247">phospholipid</z:chebi> complexes, thereby inhibiting coagulation and prolonging various clotting times </plain></SENT>
<SENT sid="4" pm="."><plain>Though appearing to be anticoagulated on ancillary testing, patients with APS are actually in a pro-thrombotic state requiring treatment with the <z:chebi fb="2" ids="50249">anticoagulants</z:chebi> <z:chebi fb="5" ids="28304">heparin</z:chebi> and <z:chebi fb="8" ids="10033">warfarin</z:chebi> </plain></SENT>
<SENT sid="5" pm="."><plain>This case discussion focuses on the recognition and treatment of thrombotic events in the setting of APS </plain></SENT>
</text></document>